Login / Signup

Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study.

Abby S Van VoorheesL Stein GoldM LebwohlBruce E StroberHoward SofenKim A PappJ BagelZ ZhangM ParisY Wang
Published in: The British journal of dermatology (2021)
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • double blind
  • coronary artery disease
  • early onset
  • high intensity
  • placebo controlled